Oral bambuterol versus terbutaline in patients with asthma
References (17)
New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma
J Allergy Clin Immunol
(1989)- et al.
Cardiopulmonary effects of terbutaline and bronchodilator combination in chronic obstructive pulmonary disease
Chest
(1980) - et al.
Bambuterol: Effective in nocturnal asthma
Respir Med
(1993) - et al.
Cardiac arrhythmias in patients with mild-to-moderate obstructive lung disease. Comparison of beta-agonist therapy alone and in combination with a xanthine derivative, enprofylline or theophylline
Chest
(1985) Difficult asthma
BMJ
(1989)- et al.
New lipophilic terbutaline ester prodrugs with long effect duration
Pharm Res
(1984) Pharmacokinetic properties of bambuterol in solution and tablet—basis for once-daily dosage in asthma
Acta Pharmacol Toxicol
(1989)- et al.
Comparison between a new once-daily anti-asthmatic drug, bambuterol, and terbutaline sustained release, twice daily
Eur Respir J
(1988)
Cited by (18)
Prodrugs of triterpenoids and their derivatives
2017, European Journal of Medicinal ChemistryCitation Excerpt :Prodrugs provide the possibilities to improve solubility, chemical stability, organoleptic property, and organ/tissue-selective delivery of the active agent, and to decrease presystemic metabolism and toxicity, which finally improves therapeutic index of the parent drugs [22,23]. Specifically, conjugation of parent drugs with phosphoric acids, sulfuric acids, amino acids, polymers, or sugars has been used to improve aqueous solubility and oral bioavailability [24–26]; masking of polar ionized groups or attachment of non-ionized functional groups (e.g. alkyl or aryl esters) has been applied to enhance lipophilicity and oral or topical absorption [20]; coupling of parent drugs with site-selective molecules has seen increased efficacy and safety [19]; protection of the metabolically labile but pharmacologically essential functional groups has shown decreased presystemic metabolism and prolonged time of drug release [27,28]. Since the late 19th century the prodrug strategy has been used to improve undesirable properties of potent drugs [29], and currently, about 10% of all globally marketed medicines can be classified as prodrugs.
Chronotherapeutics - A chronopharmaceutical approach to drug delivery in the treatment of asthma
2012, Journal of Controlled ReleaseCitation Excerpt :Bambuterol can therefore act as an inner depot from which terbutaline is slowly released. This slow-release mechanism results in a smooth and sustained plasma concentration of generated terbutaline [77–79]. Formoterol (Ciba Geigy, Europe) and salmeterol (Glaxo, UK and USA) are long-acting β2 agonist (LABA) aerosol medications, having prolonged bronchodilator activity (12 h) with substantial anti-inflammatory effect on airways, and little adverse effect [80,81].
Prodrug research: Futile or fertile?
2004, Biochemical PharmacologyCitation Excerpt :A conceptually different and particularly elegant approach to slow metabolic release has been achieved with bambuterol, a prodrug of the β2-adrenoreceptor agonist terbutaline [31,32] (Fig. 4). Compared to terbutaline 5 mg taken three times daily, bambuterol 20 mg taken once daily provides smooth and sustained plasma levels of terbutaline, and a greater symptomatic relief of asthma with a lower incidence of side-effects [33]. Similar results were obtained when comparing a slow-release formulation of terbutaline 10 mg with bambuterol 0.085 mg kg−1[34].
AuNP Pyrazolo[3,4- d]pyrimidine Nanosystem in Combination with Radiotherapy against Glioblastoma
2020, ACS Medicinal Chemistry LettersSigned, Sealed, Delivered: Conjugate and Prodrug Strategies as Targeted Delivery Vectors for Antibiotics
2019, ACS Infectious DiseasesOrganic Carbamates in Drug Design and Medicinal Chemistry
2015, Journal of Medicinal Chemistry